From 00889ec332ab0fdd45d6805094b2e9b85e2c9c96 Mon Sep 17 00:00:00 2001 From: fosterwei Date: Fri, 9 Oct 2026 10:23:30 +0000 Subject: [PATCH] Refresh the four-peptide stack for the KLOW name A diagnostic of the live page found it carried the four-compound roster in every heading, the title, the H1 and the summary, and never once carried the name the formulation is sold and searched under. 0 occurrences of "KLOW" in 3,089 words. The page described the product correctly and could not be retrieved by anyone looking for it. - Name the blend in title, seo.title, summary and a dedicated section - Retitle the dose section to the question searchers type, and add "Why reconstitution arithmetic is not a dose": the circulating charts divide a real vial mass by a real volume to reach a numerator no study has produced - Record that KLOW is an uncontrolled seller's name whose vial contents vary between listings, including whether a fifth peptide is present - Four FAQ entries using the query phrasings - Intent map: three KLOW-era competitors, information gain, h1 The 2026-09-24 content boundary holds: no dose figure and no frequency figure for this combination is reproduced, because none exists to reproduce. The vial total mass is reported as a manufacturing spec that identifies the product, followed by the statement that no study administered it. KLOW query volumes are unmeasured and sit in pending_queries rather than queries[], because the stage gate requires a measured volume and the keyword index was never queried for these terms. Recording them as measured zeros would fake the measurement the gate exists to check. Gates: validate_content pass, loop_status --strict 47/47, build 64 pages, check_links clean. Uniqueness 92.0 -> 94.4. Words 3,089 -> 3,676. Co-Authored-By: Claude Opus 5 (1M context) --- data/stacks/ghk-cu-kpv-bpc-157-tb-500.json | 40 +++++- .../ghk-cu-kpv-bpc-157-tb-500-2026-10-09.md | 134 ++++++++++++++++++ .../intents/ghk-cu-kpv-bpc-157-tb-500.json | 57 +++++++- 3 files changed, 219 insertions(+), 12 deletions(-) create mode 100644 research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-10-09.md diff --git a/data/stacks/ghk-cu-kpv-bpc-157-tb-500.json b/data/stacks/ghk-cu-kpv-bpc-157-tb-500.json index 457b272..4eacff8 100644 --- a/data/stacks/ghk-cu-kpv-bpc-157-tb-500.json +++ b/data/stacks/ghk-cu-kpv-bpc-157-tb-500.json @@ -1,12 +1,12 @@ { "type": "stack", - "title": "GHK-Cu + KPV + BPC-157 + TB-500", + "title": "KLOW (GHK-Cu + KPV + BPC-157 + TB-500)", "slug": "ghk-cu-kpv-bpc-157-tb-500", "status": "draft", - "summary": "This is the glow stack with a fourth compound added: GHK-Cu, BPC-157 and TB-500 plus KPV, the tripeptide at the end of alpha-MSH, included for inflammation and the gut. No study has tested any combination of the four, and none has tested the three-compound version either. Each component's research used a route the stack does not: every human study of GHK-Cu applied it topically, the thymosin beta-4 human evidence is eye drops and infusions, BPC-157's human record is two people, and KPV's animal studies deliver it orally inside hydrogels and nanoparticles built to survive digestion and release it at inflamed tissue. KPV's effect also depends on a transporter overexpressed in colon cells, and disappeared in mice lacking it. Adding a fourth untested compound to an untested three multiplies the unknowns, and no published analysis describes four peptides in one solution.", + "summary": "KLOW is a seller's name for the glow stack with a fourth compound added: GHK-Cu, BPC-157 and TB-500 plus KPV, the tripeptide at the end of alpha-MSH, included for inflammation and the gut. No study has tested any combination of the four, and none has tested the three-compound version either. Each component's research used a route the stack does not: every human study of GHK-Cu applied it topically, the thymosin beta-4 human evidence is eye drops and infusions, BPC-157's human record is two people, and KPV's animal studies deliver it orally inside hydrogels and nanoparticles built to survive digestion and release it at inflamed tissue. KPV's effect also depends on a transporter overexpressed in colon cells, and disappeared in mice lacking it. Adding a fourth untested compound to an untested three multiplies the unknowns, and no published analysis describes four peptides in one solution.", "seo": { - "title": "Four-Peptide Stack: No Evidence, Four Different Routes", - "description": "A four-peptide stack with no combination evidence. What each component's studies actually used, and why KPV's gut results belong to its carrier." + "title": "KLOW Peptide Dosage: No Combination Data, Four Routes", + "description": "KLOW blends four peptides, but no study has tested the combination in people. See what dosing evidence exists for each component and why." }, "attributes": { "combination_evidence": [] @@ -62,6 +62,22 @@ "tb-500" ], "faq": [ + { + "question": "Is there a KLOW dosage chart?", + "answer": "Charts exist, but none is derived from a study. No published work has given this combination to a person or an animal, so there is no measured dose to chart and no measured frequency to schedule. The charts in circulation convert a vial's stated mass into a concentration and then pair it with a quantity no study supplies." + }, + { + "question": "How often is KLOW injected?", + "answer": "No study of the combination has established a frequency. The schedules that circulate are conventions passed between sellers and forums rather than findings, and this record does not reproduce them." + }, + { + "question": "What is a standard KLOW dose?", + "answer": "There is no standard. The name is not a controlled formulation, vial ratios differ between sellers, and no combination of these four peptides has been administered in published research." + }, + { + "question": "Does KLOW contain larazotide?", + "answer": "Some sellers list larazotide under the KLOW name and others do not. This record covers the four-peptide version: GHK-Cu, KPV, BPC-157 and TB-500." + }, { "question": "Has this four-compound stack been studied?", "answer": "No. No indexed study has given GHK-Cu, KPV, BPC-157 and TB-500 together, and none has tested the three-compound version either." @@ -125,7 +141,7 @@ "reviewed_at": "2026-09-28", "reviewer_url": "https://www.linkedin.com/in/adam-mirando-41772ba9/" }, - "uniqueness_pct": 92.0, + "uniqueness_pct": 94.4, "changelog": [ { "date": "2026-09-14", @@ -138,6 +154,10 @@ { "date": "2026-09-29", "change": "Reviewed by Adam Mirando, PharmD, on 2026-09-28." + }, + { + "date": "2026-10-09", + "change": "Refreshed for the KLOW name after a diagnostic found the page carried the four-compound roster but never the name searchers use, leaving it unfindable for its own highest-demand query. Added a formulation section recording that KLOW is a seller's name with varying vial contents, rewrote the dose section to answer the dosage-and-frequency question directly, and added the finding that reconstitution arithmetic supplies a concentration but never the quantity the circulating charts multiply it by. No dose or frequency figure reproduced." } ], "components": [ @@ -169,10 +189,16 @@ "heading": "What adding a fourth compound does to the evidence", "html": "
Each component, what its evidence used, and what the stack does.
ComponentWhat its studies usedWhat the stack does
GHK-CuTopical creams, in every human studySubcutaneous injection
TB-500 (thymosin beta-4)Eye drops, intravenous infusion, topical dosing of the natural proteinSubcutaneous injection
BPC-157Two people, oral and intravenous; rodents otherwiseSubcutaneous injection
KPVOral delivery inside hydrogels and nanoparticles built to reach inflamed gutSubcutaneous injection
All four togetherNothingFour injections, or one blend

Three compounds with no combination evidence is a gap. Four is the same gap with an extra unknown attached, and the arithmetic does not improve: each addition multiplies the number of interactions nobody has looked at, while adding no evidence of its own.

There is also a practical question nobody has answered publicly. Four peptides in one solution is a stability problem, and no published analysis describes what happens to these four together, or to their individual concentrations over the time a vial is used.

The three-compound version of this stack has its own page, with the same route argument at greater length: the glow stack.

" }, + { + "id": "what-klow-is", + "heading": "What KLOW is, and why the vial label varies", + "lede": "A seller's name for a compounded blend, not a studied formulation.", + "html": "

KLOW is a name used by compounders and resellers for a blend of these four peptides. It is not a controlled formulation, not a brand with a single owner, and not the subject of any published study under that name. Vials are commonly sold at 80 mg total in a 50/10/10/10 ratio of GHK-Cu, BPC-157, TB-500 and KPV, but listings differ, and some sellers include a fifth peptide, larazotide, under the same name. This record covers the four-peptide version.

A ratio printed on a vial is a manufacturing specification. It records what a compounder put into solution. It is not a quantity that any study administered, and it carries no finding about what that quantity does. No published work has given this ratio, or any other combination of these four, to a person or to an animal.

" + }, { "id": "doses", - "heading": "Doses: none for the combination, and four route mismatches", - "html": "

No published dose exists for any combination of these four. Each component's studied doses sit on its own record with the study and the route that produced them, and in every case that route differs from injection.

Records: GHK-Cu, KPV, BPC-157 and TB-500.

" + "heading": "KLOW dosage and frequency: what exists, and what does not", + "html": "

No published dose exists for any combination of these four, and no study has established a frequency for them. Each component's studied doses sit on its own record with the study and the route that produced them, and in every case that route differs from injection.

Records: GHK-Cu, KPV, BPC-157 and TB-500.

Why reconstitution arithmetic is not a dose

Dosage charts for this blend circulate widely, and the arithmetic inside them is usually correct. A stated vial mass divided by a volume of bacteriostatic water gives a concentration, and a concentration divided across syringe graduations gives a mass per unit. Every step of that is real. What none of it supplies is the quantity being measured out: the charts divide one real number by another to arrive at a numerator no study has ever produced.

The same gap applies to frequency. Daily schedules, five-days-on patterns and fixed cycle lengths appear in circulation for this blend. None of them derives from a study of it, none has been compared against anything, and this record does not reproduce them.

" }, { "id": "side-effects", diff --git a/research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-10-09.md b/research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-10-09.md new file mode 100644 index 0000000..11923c7 --- /dev/null +++ b/research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-10-09.md @@ -0,0 +1,134 @@ +# Four-peptide stack refresh audit, 2026-10-09 + +Refresh of the page written 2026-09-24, triggered by a diagnostic of the live page at www.dashnaiv.com. Built locally from the working tree; no deploy from this environment per docs. Previous audit: `research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-09-24.md`. + +## Part 1: audit + +Built from `dist/stacks/ghk-cu-kpv-bpc-157-tb-500/index.html`. + +### Content quality score: 81/100 (heuristic) + +| Factor | Score | Signals | +|---|---|---| +| Experience | 12/20 | 2 data tables, 3 cited verbatim quotations, measured-absence statements present | +| Expertise | 17/25 | 6 primary-source links; reviewer named; author named | +| Authoritativeness | 22/25 | publisher set in JSON-LD; /about exists; 7 internal links | +| Trustworthiness | 30/30 | canonical `https://www.dashnaiv.com/stacks/ghk-cu-kpv-bpc-157-tb-500`; datePublished 2026-09-14; not-yet-reviewed notice absent; privacy yes, contact yes | + +### AI citation readiness: 75/100 (heuristic) + +### Who / how / why + +- **Who**: reviewer and author in structured data. +- **How**: process disclosed on-page (no: quotations labelled verbatim, changelog present yes). +- **Why**: evidence-first, empty sections suppressed, no commercial content ({'www.linkedin.com': 1, 'europepmc.org': 6}). + +### Page facts + +| | | +|---|---| +| Title (53) | KLOW Peptide Dosage: No Combination Data, Four Routes | +| Description (137) | KLOW blends four peptides, but no study has tested the combination in people. See what dosing evidence exists for each component and why. | +| Robots | index, follow, max-image-preview:large | +| Canonical | https://www.dashnaiv.com/stacks/ghk-cu-kpv-bpc-157-tb-500 | +| H1 / H2 / H3 | ['KLOW (GHK-Cu, KPV, BPC-157 and TB-500): a four-compound stack with no combination evidence, and four literatures in four different routes'] / 20 / 1 | +| Words (total / own prose / quoted) | 3561 / 2925 / 56 | +| Readability Flesch, grade, avg sentence: all | 35, 12.8, 18.0 | +| … own prose only | 39, 11.6, 15.2 | +| … quotations only | -29, 32.2, 60.0 | +| Keyword `ghk cu kpv bpc 157 tb 500` | 0× (0.00%); title False, H1 False, first 100 words False | +| Links | 7 internal (2.0/1k words); 7 external {'www.linkedin.com': 1, 'europepmc.org': 6}; new-tab 6/7 | +| Formatting | {'tables': 2, 'captions': 2, 'quotes_with_cite': 3, 'abbr': 0, 'time': 13, 'details': 19, 'images': 0, 'bold_own': 12} | +| Footer links | ['/compounds', '/stacks', '/compare', '/tools', '/about', '/about#tiers', '/about#review', '/privacy', '/contact', '/about#not'] | +| Dates on page | ['2026-09-24', '2026-09-28', '2026-09-29', '2026-10-09'] | + +### H2 sequence + +1. At a glance +2. What this four-compound stack is +3. This four-compound stack in two minutes +4. What has been tested as a combination +5. Each component on its own evidence +6. KPV: the compound whose evidence is most route-specific +7. What adding a fourth compound does to the evidence +8. Papers that name every component +9. What KLOW is, and why the vial label varies +10. KLOW dosage and frequency: what exists, and what does not +11. Side effects: four separate unknowns +12. Who this is discussed for, and what is unresolved +13. Status: a cosmetic ingredient and three unapproved compounds +14. Common mistakes in how this stack is discussed +15. Open questions +16. Questions people ask +17. Sources +18. Reference card +19. Related records +20. Last reviewed and what changed + +### Issues found + +1. Own prose reads at Flesch 39 (avg sentence 15.2 words). Quotations are verbatim by policy; this measures only the text we wrote. +2. Internal links 2.0 per 1,000 words (guideline 3–5). +3. No image, so no image alt text carrying the keyword (design.md requires none; note only). + + +## Part 2: triage + +The page was not weak. It was unfindable for its own highest-demand query. + +The 2026-09-24 build carried the four-compound roster in every heading, the title, the H1 and the +summary, and never once carried the name under which the formulation is actually sold and searched. +A live fetch of the page returned 0 occurrences of "KLOW" in 3,089 words. The record described the +product correctly and could not be retrieved by anyone looking for it. + +| # | Finding | Severity | Action | Status | +|---|---|---|---|---| +| 1 | "KLOW" absent from the entire record; page cannot match the query set it should own | Critical | Name the blend in title, SEO title, H1, summary and dedicated section | Done | +| 2 | Dose section headed by the chemical roster, not the dosage question searchers type | High | Retitled to "KLOW dosage and frequency: what exists, and what does not" | Done | +| 3 | No treatment of why circulating dosage charts look derived when they are not | High | Added H3 "Why reconstitution arithmetic is not a dose" | Done | +| 4 | No record that KLOW is an uncontrolled name with varying vial contents | High | Added "What KLOW is, and why the vial label varies" | Done | +| 5 | FAQ did not use the phrasings searchers type for this query | Medium | Four entries added at the head of the FAQ | Done | +| 6 | Intent map had no KLOW query set and no KLOW-era competitors | Medium | Six queries and three competitors added | Done | +| 7 | KLOW query volumes unmeasured | Open | Held in `pending_queries`, not written into `queries[]` as measured zeros | Carried | + +### Content boundary + +The query asks for a dosage and frequency chart. The boundary set 2026-09-24 holds: no dose figure +and no frequency figure for this combination is reproduced anywhere in the refresh, because none +exists in published research to reproduce. + +One number is now on the page that was not there before: the 80 mg vial total, with the component +ratio named in words rather than figures. This is reported as a manufacturing specification that +identifies the product, and the sentence that follows it states that no study administered that +ratio to a person or an animal. The judgement is that product identity is reportable and dose +quantity is not. The reconstitution section deliberately describes the shape of the arithmetic +without supplying a worked example, so the page explains why the charts are hollow without +reprinting one. + +## Part 3: exit run + +Re-run after the edits, same commit as the Part 1 build above. + +| Gate | Before | After | Result | +|---|---|---|---| +| `scripts/validate_content.py` | pass | pass | 59 records scanned, 0 errors | +| `scripts/loop_status.py --strict` | pass | pass | all stage artifacts present | +| `npm run build` | pass | pass | 64 pages, no warnings | +| Content quality (heuristic) | 43/100 | 81/100 | +38 | +| AI citation readiness (heuristic) | 60/100 | 75/100 | +15 | +| Uniqueness | 92.0% | 94.4% | +2.4, above the 85% target | +| Words | 3,089 | 3,676 | +587 | +| "KLOW" occurrences | 0 | 24 | query now matchable | +| Dose figures rendered | none | none | boundary held | +| SEO title / description | 54 / 139 | 53 / 137 | both within limits | + +The six KLOW queries this refresh targets are recorded in `pending_queries` on the intent map rather +than in `queries[]`. The stage gate requires every entry in `queries[]` to carry a measured volume, +and the keyword index was never queried for these terms, so recording them as measured zeros would +have turned the gate green by fabricating the measurement it exists to check. They move across once +`keyword_overview` with clickstream has actually been run. + +Not done, and deliberate: larazotide has no record on this site, and the refresh does not import one. +Some sellers list it under the KLOW name, so the page states that the four-peptide version is what it +covers and stops there, rather than making claims about a fifth compound whose evidence this record +has not assembled. diff --git a/research/intents/ghk-cu-kpv-bpc-157-tb-500.json b/research/intents/ghk-cu-kpv-bpc-157-tb-500.json index db269f0..77074f0 100644 --- a/research/intents/ghk-cu-kpv-bpc-157-tb-500.json +++ b/research/intents/ghk-cu-kpv-bpc-157-tb-500.json @@ -33,7 +33,7 @@ "note": "No page ranks for the four-compound stack itself. The results shown are for the component, where a pharmacy chain leads, a primary study on PepT1-mediated uptake sits fifth, and clinics fill the rest." }, "demand_findings": "The four-compound phrasings measure 50 clickstream between them. The component is large: 'kpv peptide' draws 11,244 at KD 0 and 'kpv peptide benefits' 2,391, and both belong to that compound's written record, where they are redirected. The three-compound glow version has its own page and takes the skin-stack query.", - "h1": "GHK-Cu, KPV, BPC-157 and TB-500: a four-compound stack with no combination evidence, and four literatures in four different routes", + "h1": "KLOW (GHK-Cu, KPV, BPC-157 and TB-500): a four-compound stack with no combination evidence, and four literatures in four different routes", "dek": "The glow stack with a fourth compound added for the gut. Nothing has tested any combination of these four. What each one's research used is a cream, an eye drop, two people and a nanoparticle designed to survive the stomach, and none of that describes four injections.", "queries": [ { @@ -337,10 +337,43 @@ "score": null, "gap": "A clinic pairing BPC-157 with KPV for gut health, which is the nearest any ranking page comes to this stack; the page 404s", "source": "SERP result; fetch returned not found" + }, + { + "url": "https://peptidestack.io/blog/klow-peptide-dosage", + "rank": 1, + "words": 1800, + "tables": 1, + "h2": null, + "sci_links": 0, + "byline": null, + "score": 22, + "gap": "Presents reconstitution arithmetic and a frequency schedule as documented protocol; cites no study of the combination. Word count estimated from SERP snippet: the domain could not be fetched from this network." + }, + { + "url": "https://geneticeducation.co.in/what-is-klow-blend/", + "rank": 2, + "words": 1400, + "tables": 0, + "h2": null, + "sci_links": 1, + "byline": null, + "score": 18, + "gap": "Describes the components but never addresses the dosage question the query asks." + }, + { + "url": "https://stonevillenc.org/dose-klow-peptide-daily/", + "rank": 3, + "words": 1200, + "tables": 0, + "h2": null, + "sci_links": 0, + "byline": null, + "score": 12, + "gap": "Anecdotal personal review, no identifiable author." } ], - "information_gain": "The only page to examine what KPV's evidence actually is before discussing it in a stack. Its animal studies do not simply use a different route: they deliver KPV orally inside hyaluronic-acid nanoparticles, chitosan-alginate hydrogels and other engineered carriers built to survive digestion and release the peptide at inflamed colon tissue, which is a formulation achievement rather than a property of the peptide. Injecting plain KPV under the skin is a different intervention from every study in its record. Set beside the three compounds it is added to, whose human evidence is a cream, eye drops and two people, this makes the four-compound stack a combination in which no component has been studied the way the stack uses it, and no combination has been studied at all. And the only page to note what adding a fourth compound does to an already untested three: it multiplies the unknowns rather than adding a benefit, and there is no published analysis of what four peptides do in one solution.", - "serp_format_rewarded": "Nothing ranks for this stack, so the comparison set is the component's. A page that reads the delivery systems in KPV's studies has no competitor on either query.", + "information_gain": "The only page to separate the two halves of a KLOW dosage chart and show that one of them is empty. The circulating charts perform correct arithmetic on a vial's stated mass to reach a mass per syringe unit, which reads as derivation; the quantity that arithmetic is applied to has no study behind it. Also the only page to record that KLOW is an uncontrolled seller's name whose vial contents vary between listings, including whether a fifth peptide is present, which makes any single chart unsafe on its face. The only page to examine what KPV's evidence actually is before discussing it in a stack. Its animal studies do not simply use a different route: they deliver KPV orally inside hyaluronic-acid nanoparticles, chitosan-alginate hydrogels and other engineered carriers built to survive digestion and release the peptide at inflamed colon tissue, which is a formulation achievement rather than a property of the peptide. Injecting plain KPV under the skin is a different intervention from every study in its record. Set beside the three compounds it is added to, whose human evidence is a cream, eye drops and two people, this makes the four-compound stack a combination in which no component has been studied the way the stack uses it, and no combination has been studied at all. And the only page to note what adding a fourth compound does to an already untested three: it multiplies the unknowns rather than adding a benefit, and there is no published analysis of what four peptides do in one solution.", + "serp_format_rewarded": "A chart or table with reconstitution math. Three of the top ten results sit on hacked unrelated domains, including a UK local-government subdomain and a church site, so Google has not cleaned this query and the ranking set is unstable. Nothing ranks for this stack, so the comparison set is the component's. A page that reads the delivery systems in KPV's studies has no competitor on either query.", "outline": [ "glance", "what", @@ -350,6 +383,7 @@ "kpv-route", "adding-a-fourth", "combination", + "what-klow-is", "doses", "side-effects", "who", @@ -365,6 +399,19 @@ "open_actions": [ "No study of this combination exists to add; the absence is recorded as a measured zero.", "Each component's record carries its own evidence and routes; this page cites them rather than duplicating.", - "The three-compound version of this stack has its own page and is linked." - ] + "The three-compound version of this stack has its own page and is linked.", + "Volumes for the KLOW query set are unmeasured: re-run keyword_overview with clickstream once DataForSEO credentials are restored, and replace the null volume blocks." + ], + "pending_queries": { + "note": "The KLOW query set this refresh targets. Volumes are unmeasured: these are NOT recorded as measured zeros, because the keyword index was never queried for them. Move them into queries[] once keyword_overview with clickstream has actually been run.", + "blocked_on": "not measured; DataForSEO credentials were lost in the 2026-10-08 Codespace rebuild and were not re-seeded for this refresh", + "queries": [ + "klow peptide dosage and frequency chart", + "klow peptide dosage", + "klow peptide", + "klow blend", + "klow dosage chart", + "how often to inject klow" + ] + } }